Immunome, Inc. (IMNM)
NASDAQ:IMNM
Want to see IMNM full AI Analyst Report?
Top Page
Immunome
(NASDAQ:IMNM)
Select Model
Select Model
Rating:49Neutral
Price Target:
$22.00
▼(-10.68% Downside)
Action:Reiterated
Date:05/14/26
The score is primarily held down by weak financial performance driven by heavy cash burn and large losses alongside declining revenue, despite low leverage. Technicals are mixed with neutral-to-soft momentum, and valuation support is limited because the company is unprofitable and no dividend yield is provided.
Positive Factors
NDA submission & Phase 3 success
A successful Phase 3 and NDA submission for varegacestat is a structural milestone: it converts a program from R&D to potential commercial product, materially changing cash generation prospects, partner leverage, and long-term revenue optionality if approved and launched.
Negative Factors
Heavy operating cash burn
Persistent, large negative operating and free cash flows create durable funding pressure. Even with runway guidance, the magnitude and worsening trend of cash burn elevate dilution and financing risk, forcing dependence on external capital or partnership monetization.
Read all positive and negative factors
Positive Factors
Negative Factors
NDA submission & Phase 3 success
A successful Phase 3 and NDA submission for varegacestat is a structural milestone: it converts a program from R&D to potential commercial product, materially changing cash generation prospects, partner leverage, and long-term revenue optionality if approved and launched.
Read all positive factors
Immunome (IMNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.45B
Dividend YieldN/A
Average Volume (3M)954.34K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth-63.29%
EPS Growth25.39%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.39
Shares Outstanding113,250,400
10 Day Avg. Volume1,220,634
30 Day Avg. Volume954,341
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue371.51
Enterprise Value/Gross Profit-31.97
Enterprise Value/Ebitda-6.39
Forecast
1Y Price Target
$35.17Price Target Upside42.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$2.51M
Immunome Business Overview & Revenue Model
Company Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of ...
How the Company Makes Money
Immunome primarily generates revenue through (1) collaboration and licensing arrangements with other pharmaceutical/biotechnology companies, which may include upfront payments, research funding, milestone payments tied to development/regulatory ac...
Immunome Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.01M | 6.94M | 9.04M | 14.02M | 0.00 | 0.00 |
| Gross Profit | -46.65M | 3.99M | 9.04M | 14.02M | 0.00 | 0.00 |
| EBITDA | -233.29M | -211.16M | -151.35M | -28.00M | -36.27M | -24.45M |
| Net Income | -224.59M | -212.39M | -292.96M | -106.81M | -36.90M | -24.71M |
Balance Sheet | ||||||
| Total Assets | 619.79M | 683.19M | 240.24M | 148.54M | 24.05M | 57.92M |
| Cash, Cash Equivalents and Short-Term Investments | 582.69M | 653.48M | 217.30M | 138.14M | 20.32M | 49.23M |
| Total Debt | 3.69M | 3.85M | 4.83M | 1.65M | 291.00K | 317.00K |
| Total Liabilities | 31.11M | 48.84M | 59.08M | 28.66M | 7.39M | 9.74M |
| Stockholders Equity | 588.69M | 634.34M | 181.16M | 119.88M | 16.65M | 48.19M |
Cash Flow | ||||||
| Free Cash Flow | -205.52M | -200.60M | -164.30M | -8.40M | -28.94M | -18.30M |
| Operating Cash Flow | -196.50M | -190.92M | -110.79M | -7.57M | -28.69M | -18.23M |
| Investing Cash Flow | 43.70M | 60.80M | -85.06M | -30.48M | -248.00K | -79.00K |
| Financing Cash Flow | 477.99M | 640.36M | 240.53M | 116.41M | 32.00K | 27.77M |
Immunome Technical Analysis
Positive
24.63
Price Trends
22.01
Negative
22.35
Negative
18.47
Positive
Market Momentum
-0.32
Positive
47.38
Neutral
59.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 24.63 is above the 20-day moving average (MA) of 22.33, above the 50-day MA of 22.01, and above the 200-day MA of 18.47, indicating a neutral trend. The MACD of -0.32 indicates Positive momentum. The RSI at 47.38 is Neutral, neither overbought nor oversold. The STOCH value of 59.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.
Immunome Risk Analysis
Immunome disclosed 75 risk factors in its most recent earnings report. Immunome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immunome Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.58B | -9.66 | -56.07% | ― | 3.42% | -11.04% | |
52 Neutral | $2.93B | -16.50 | -41.54% | ― | 39.04% | 32.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.45B | -11.49 | -51.15% | ― | -63.29% | 25.39% | |
47 Neutral | $1.56B | -4.88 | -45.47% | ― | -72.09% | -754.83% | |
47 Neutral | $821.15M | -68.46 | -28.90% | ― | 68.64% | 50.57% | |
43 Neutral | $854.36M | -4.22 | -161.87% | ― | ― | -6.15% |
* Healthcare Sector Average
IMNM
Immunome
21.66
13.06
151.86%
GERN
Geron
1.28
-0.17
-11.72%
IMTX
Immatics
11.62
6.51
127.40%
TNGX
Tango Therapeutics
20.24
18.19
887.32%
TSHA
Taysha Gene Therapies
5.49
2.89
111.15%
SANA
Sana Biotechnology
3.07
1.07
53.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.